Compliance & Audits

DEA Telehealth Controlled Substance Prescribing Flexibility Expires

The Fourth Temporary Extension Runs Out December 31, 2026, and the Special Registration Rule Still Isn't Final

Without further action, telemedicine prescribing of Schedule II-V controlled substances without a prior in-person exam becomes prohibited starting January 1, 2027.

Summary of the Rule or Edit Change

The DEA and HHS's fourth temporary extension of telemedicine controlled substance prescribing flexibilities, issued December 30, 2025, runs through December 31, 2026. It covers Schedule II through V controlled substances prescribed via telemedicine and applies uniformly regardless of when the practitioner-patient relationship started. The permanent fix, a special registration framework first proposed in January 2025 after drawing more than 40,000 public comments, entered White House OMB review on August 25, 2026. As of this writing the DEA hasn't disclosed its contents, and there is no confirmation it will be finalized before the current flexibility lapses.

Separately, and already in effect, a final rule covering buprenorphine prescribing for opioid use disorder took effect December 31, 2025. That rule requires synchronous audio-visual technology, not audio-only, for a qualifying telemedicine encounter and layers in its own practitioner registration requirement, independent of the broader Schedule II-V deadline below.

The underlying Ryan Haight Act requirement for a prior in-person medical evaluation before prescribing a controlled substance has never been repealed. The temporary extensions are what's been waiving it since the COVID-19 public health emergency. If the extensions lapse without a replacement framework, that in-person requirement doesn't need new rulemaking to come back into force.

Action Required for Billing Teams

  • Pull a patient-level list now of every patient receiving a Schedule II-V prescription through a telehealth-only relationship, meaning no in-person visit has occurred since the prescribing relationship began.
  • Prioritize Schedule II patients (stimulants, for example) for in-person scheduling before December calendars fill up industry-wide.
  • Confirm OUD/buprenorphine telehealth visits already meet the audio-visual and registration requirements that took effect December 31, 2025, since that piece is active regardless of what happens next.
  • Check your state medical board's own telehealth prescribing rules independently; a number of states layer additional requirements on top of whatever the DEA allows federally.
  • Watch the Federal Register for the special registration final rule text, since its specific requirements, not just its existence, will determine your 2027 compliance workload.

For the full breakdown of who's exposed and what to track between now and January 1, read our DEA telehealth prescribing deadline guide.

Verifiable References

  1. Holland & Knight. DEA and HHS Extend Telemedicine Prescribing Flexibilities Through 2026. hklaw.com/insights/dea-and-hhs-extend-telemedicine-prescribing-flexibilities-2026
  2. Alliance for Connected Care, ConnectWithCare.org. DEA Prescribing of Controlled Substances: Days Until Fourth Extension Runs Out. connectwithcare.org/dea-prescribing-of-controlled-substances
  3. Jones Day. DEA Releases Rules on Telemedicine Prescribing of Controlled Substances, Proposes Special Registrations. jonesday.com/insights/dea-releases-rules-telemedicine-prescribing-special-registrations

Need Your Telehealth Prescribing Exposure Mapped Out?

Rcmaxis helps practices identify at-risk telehealth-only controlled substance patients before the deadline hits.

Get Your Free Revenue Assessment